Abacus Medicine Pharma Services is the new name for the healthcare and pharma services company previously known as Aposave.
Simon Estcourt, Managing Director, Abacus Medicine Pharma Services explains the rebranding:
“The new brand makes it very clear who we are and what we do. The closer association with the Abacus Medicine Group will give confidence to clients, healthcare professionals and suppliers that we are a division of a large and successful organisation, that we are well backed financially and that we are planning for a long and healthy future.”
“The rebrand comes at a good time for the company as we have plans to develop our access to the US and Chinese markets. Our value proposition is based around providing new generation services to our global client base. We made an excellent start as Aposave and now as Abacus Medicine Pharma Services we plan to make significant strides forward.”
A global footprint
The Abacus Medicine Group has been providing better access to pharmaceutical products and better healthcare to European countries and their populations for close to 20 years. This has been achieved through its parallel distribution division.
In order to establish a global footprint for the organisation, the group established a full healthcare and pharma services divisionwith commercial headquarters in the UK in 2020. Today, Abacus Medicine Pharma Services has companies in the USA, United Kingdom, Denmark, Hong Kong and The Netherlands.
Abacus Medicine Pharma Services has three service lines: Clinical Trial Solutions (CTS), Commercial Partnerships (CP) and Unlicensed Medicines (ULM).
- The CTS service focuses on comparator sourcing solutions for clinical trials as well as bespoke batch-specific sourcing of pre-clinical samples
- The CP service focuses on innovative distribution solutions for rare and orphan products across the European market
- The ULM service provides a highly personalised approach to delivering life-saving products to patients that require access to them anywhere around the globe
